undamentalytics Newsletter
Sign in

Crescent Biopharma, Inc. revenue

Crescent Biopharma, Inc.'s revenue was $10.8m in fiscal 2025, up 108340.0% on the year before. Since fiscal 2012 ($15.3m) it has grown at a compound -3.7% a year.

Revenue history

US$ millions unless shown otherwise. Fiscal years, plus the last twelve months (LTM) when newer.

Fiscal year2012Dec 20122013Dec 20132014Dec 20142015Dec 20152016Dec 20162020Dec 20202021Dec 20212022Dec 20222023Dec 20232025Dec 2025
Revenue154152001010011
Growth on the year before—−73.8%+276.4%+33.6%−99.9%+>999%−88.6%−93.5%−86.7%+>999%

Revenue as reported in the company's 10-K and 10-Q filings (for banks, net interest income plus non-interest income). Growth is left blank when the earlier figure was zero or negative.

Revenue against peers

Biotechnology: the closest covered companies by revenue. Last twelve months.

CompanyRevenueGrowth3-year growth a year
Crescent Biopharma, Inc. $1.2m -88.6% 84.4%
Longeveron Inc. $1.2m -42.7% 10.4%
Shattuck Labs, Inc. $1.0m -66.6% 5.2%
Dare Bioscience, Inc. $1.4m 4366.5% —
Medicinova Inc $920,481 875.7% —
Cartesian Therapeutics, Inc. $1.5m 44.0% -68.8%

Compare with peers

Head to head: CBIO vs LGVNCBIO vs STTKCBIO vs DARE

More: Biotechnology stocks compared, Health Care sector, rankings of US companies

Figures from Crescent Biopharma, Inc.'s SEC filings (10-K and 10-Q), retrieved November 1, 2026. How we read and check them: methodology and data sources. Not investment advice. Back to Crescent Biopharma, Inc.